Novocure Ltd. (NVCR): Price and Financial Metrics

Novocure Ltd. (NVCR): $60.40

2.16 (+3.71%)

POWR Rating

Component Grades














  • NVCR scores best on the Quality dimension, with a Quality rank ahead of 65.24% of US stocks.
  • The strongest trend for NVCR is in Stability, which has been heading down over the past 177 days.
  • NVCR's current lowest rank is in the Sentiment metric (where it is better than 0.67% of US stocks).

NVCR Stock Summary

  • Price to trailing twelve month operating cash flow for NVCR is currently 195.82, higher than 98.2% of US stocks with positive operating cash flow.
  • NVCR's price/sales ratio is 11.21; that's higher than the P/S ratio of 90.77% of US stocks.
  • Over the past twelve months, NVCR has reported earnings growth of 101.93%, putting it ahead of 86.79% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to NOVOCURE LTD, a group of peers worth examining would be ALTR, FROG, EB, ALGM, and QLYS.
  • To check out NOVOCURE LTD's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001645113.

NVCR Valuation Summary

  • NVCR's price/sales ratio is 11.2; this is 489.47% higher than that of the median Healthcare stock.
  • NVCR's price/earnings ratio has moved down 49.1 over the prior 91 months.

Below are key valuation metrics over time for NVCR.

Stock Date P/S P/B P/E EV/EBIT
NVCR 2023-03-24 11.2 13.7 -65.2 -72.6
NVCR 2023-03-23 11.1 13.6 -64.7 -72.2
NVCR 2023-03-22 11.1 13.5 -64.3 -71.7
NVCR 2023-03-21 11.5 14.0 -66.9 -74.4
NVCR 2023-03-20 11.5 14.0 -66.6 -74.1
NVCR 2023-03-17 11.2 13.6 -65.0 -72.5

NVCR Growth Metrics

    The 3 year net cashflow from operations growth rate now stands at 507.53%.
  • Its 3 year revenue growth rate is now at 100.32%.
  • Its year over year net cashflow from operations growth rate is now at -43.76%.
Over the past 67 months, NVCR's revenue has gone up $437,909,000.

The table below shows NVCR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 542.624 48.899 -81.689
2022-06-30 545.232 50.879 -68.237
2022-03-31 539.365 64.665 -36.54
2021-12-31 535.031 82.756 -58.351
2021-09-30 545.771 121.833 -26.976
2021-06-30 544.825 128.402 -4.568

NVCR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVCR has a Quality Grade of B, ranking ahead of 83.73% of graded US stocks.
  • NVCR's asset turnover comes in at 0.503 -- ranking 92nd of 186 Medical Equipment stocks.
  • IDXG, HAE, and CTSO are the stocks whose asset turnover ratios are most correlated with NVCR.

The table below shows NVCR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.503 0.792 -0.008
2021-06-30 0.597 0.795 0.016
2021-03-31 0.685 0.794 0.047
2020-12-31 0.786 0.785 0.059
2020-09-30 0.926 0.771 0.057
2020-06-30 0.837 0.761 0.019

NVCR Price Target

For more insight on analysts targets of NVCR, see our NVCR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $177.14 Average Broker Recommendation 2.06 (Hold)

NVCR Stock Price Chart Interactive Chart >

Price chart for NVCR

NVCR Price/Volume Stats

Current price $60.40 52-week high $120.03
Prev. close $58.24 52-week low $56.06
Day low $58.34 Volume 160,173
Day high $60.80 Avg. volume 1,039,020
50-day MA $76.90 Dividend yield N/A
200-day MA $77.10 Market Cap 6.37B

Novocure Ltd. (NVCR) Company Bio

NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.

NVCR Latest News Stream

Event/Time News Detail
Loading, please wait...

NVCR Latest Social Stream

Loading social stream, please wait...

View Full NVCR Social Stream

Latest NVCR News From Around the Web

Below are the latest news stories about NOVOCURE LTD that investors may wish to consider to help them evaluate NVCR as an investment opportunity.

12 Most Promising Healthcare Stocks According to Analysts

In this article, we will take a look at the 12 most promising healthcare stocks according to analysts. To see more such companies, go directly to 5 Most Promising Healthcare Stocks According to Analysts. 2023 is turning out to be a horrific year for financial markets as investors are starting to see a glimpse of […]

Yahoo | March 29, 2023

Kristin Stafford Joins Novocure Board of Directors

ROOT, Switzerland, March 29, 2023--Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors.

Yahoo | March 29, 2023

Institutional investors may adopt severe steps after NovoCure Limited's (NASDAQ:NVCR) latest 7.3% drop adds to a year losses

Key Insights Given the large stake in the stock by institutions, NovoCure's stock price might be vulnerable to their...

Yahoo | March 16, 2023

Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

ROOT, Switzerland, March 16, 2023--Novocure today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.

Yahoo | March 16, 2023

2 Best Defensive Stocks to Buy in March

Keeping with this theme, Federal Reserve Chair Jerome Powell said Tuesday that the bank is considering raising interest rates faster and farther than previously anticipated in order to tamp down inflation. Defensive stocks could be a good way to protect your portfolio from downside risk. Which defensive stocks are top buys right now?

Yahoo | March 8, 2023

Read More 'NVCR' Stories Here

NVCR Price Returns

1-mo -20.82%
3-mo -17.66%
6-mo -20.51%
1-year -27.10%
3-year -10.31%
5-year 177.06%
YTD -17.66%
2022 -2.30%
2021 -56.61%
2020 105.34%
2019 151.70%
2018 65.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.907 seconds.